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Abstract
Introduction: Two species of Ehrlichia are known to cause human illness. Several other species
have been discovered in ticks and animals, and recent reports suggest that some of these Ehrlichia
species might be human pathogens. We report here the first association of a recently discovered
pathogen, the Panola Mountain Ehrlichia species, with a case of human illness.
Case presentation: A 31-year-old man from Atlanta, Georgia (GA) in the United States of
America (USA) presented with a persistent sore neck of 3 weeks duration following a tick bite.
DNA from the Panola Mountain Ehrlichia species, which was recently discovered in a goat in
Georgia, was detected in an acute blood sample. Serologic testing was inconclusive. Polymerase
chain reaction tests for other tick-borne diseases found in this region were negative. The patient
rapidly improved in response to doxycycline therapy.
Conclusion: Detection of Ehrlichia DNA in an acute blood sample meets the Centers for Disease
Control and Prevention laboratory confirmation criteria for ehrlichiosis, and response to
doxycycline provides supporting clinical evidence. The Panola Mountain Ehrlichia  species, an
emerging pathogen transmitted by ticks in the eastern USA, should be considered as a possible
cause of tick-borne illness in this region.
Introduction
Ehrlichia species are tick-transmitted intracellular bacteria
closely related to Anaplasma, Neorickettsia and Rickettsia.
Ehrlichia chaffeensis was first described as a human patho-
gen in 1986 and E. ewingii in 1996 [1], and recent evi-
dence suggests that other species of Ehrlichia might also
cause illness [2,3]. A new species of Ehrlichia, the Panola
Mountain Ehrlichia species, was recently discovered in the
USA [4]. Clinical signs of ehrlichial infection are often
non-specific, and the most common signs are fever, head-
ache, myalgia and malaise [1]. Laboratory diagnosis of
ehrlichiosis depends on the detection of ehrlichiae in
samples collected during the acute illness or on demon-
stration of a significant rise (four-fold or greater) in anti-
body titer between the acute and convalescent phases of
the illness [1,5]. Serology is limited because acute serol-
ogy alone is insufficient to diagnose infection, paired
serology does not provide a diagnosis until 3 to 4 weeks
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after empirical treatment has been initiated, and only E.
chaffeensis is available for serologic testing of humans [1].
Diagnosis of ehrlichiosis during the acute infection
increasingly relies on polymerase chain reaction (PCR)
[1,6]. According to the official case definition used by the
Centers for Disease Control (CDC) and the USA National
Notifiable Diseases System, a positive PCR reaction, with
confirmation of the amplicon identity, is sufficient for
laboratory confirmation of a case of human ehrlichiosis
[5].
Case presentation
On 23 September 2005, a 31-year-old Caucasian man
from Atlanta, Georgia, USA presented with a complaint of
neck soreness for 3 weeks. The patient reported hiking at
Panola Mountain State Park in Georgia on 31 August
2005 and later removing a partially engorged nymphal
tick from his upper arm on 3 September. The patient
stored the tick in an empty vial at room temperature, and
the tick was later identified as Amblyomma americanum.
On 8 September, the patient began suffering from a per-
sistent sore neck, characterized by musculoskeletal pain
upon turning his head and insomnia due to pain. The
pain was refractory to anti-inflammatory medications,
including acetaminophen, aspirin and ibuprofen. Physi-
cal examination on 23 September was unremarkable.
Pyrexia was not observed and no erythema or edema was
noted at the site of the tick bite; however, the patient had
taken 500 mg aspirin prior to examination. The patient
was treated for a presumptive tick-borne illness with 100
mg of oral doxycycline twice daily for 10 days. The patient
reported that neck soreness was improved by 48 to 60
hours after doxycycline therapy was initiated.
Laboratory testing
Blood was drawn from the patient on 23 September for
PCR testing for tick-borne diseases, on 26 September for a
complete blood count (CBC) and acute serology, and on
15 October for convalescent serology. Whole blood from
23 September and sera from 26 September and 15 Octo-
ber were submitted to the CDC for tick-borne disease test-
ing. The CBC was performed by Quest Diagnostics
(Nichols Institute, Chantilly, VA), and CBC results (Table
1) were within the normal reference range for this labora-
tory.
For PCR testing, DNA was extracted from 100 µl of clotted
blood and from the dead tick, using an IsoQuick Nucleic
Acid Extraction Kit (ORCA Research Inc., Bothell, WA).
We detected DNA from Ehrlichia using a genus-specific,
hemi-nested PCR with the outer primers EC12A and HE3
[4], followed by a hemi-nested reaction using the 'For-
ward' primer [7] and HE3. DNA from Rickettsia species
was detected using primer-1 and primer-2 [8]. We
assessed the quality of the tick DNA using primers T1B
and T2A [9]. Positive and negative controls were used for
all assays and consisted of genomic DNA from Rickettsia
rickettsii, Ehrlichia ewingii or distilled water. All PCR prod-
ucts were purified with a QIAquick PCR Purification Kit
(Qiagen, Valencia, CA) and sequenced in duplicate using
PCR primers and a BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA).
Sequences were determined using an ABI 3100 (Applied
Biosystems). Primer sequences were removed and
sequences assembled with Seqmerge (Accelrys, San Diego,
CA).
Using the hemi-nested PCR, an amplicon from the 16S
rRNA gene of an Ehrlichia species was obtained from the
acute blood sample. The amplicon was sequenced, and
the 361-bp sequence (GenBank accession number
DQ217573) was 100% identical to the sequence reported
from the Panola Mountain Ehrlichia species (Ehrlichia spe-
cies P-Mtn, GenBank accession number DQ324367). The
amplicon was not identical to sequences from any other
species represented in GenBank. No DNA from Rickettsia
was detected in the patient's blood. The tick was poorly
preserved by the patient, and DNA could not be amplified
from it.
For acute and convalescent serology, sera from 26 Septem-
ber and 15 October were tested using indirect immunoflu-
orescence assays (IFA), performed as previously described
[10], to detect antibodies against Anaplasma phagocy-
tophilum, Borrelia burgdorferi, Coxiella burnetii, Francisella
tularensis, Rickettsia africae, R. akari, 'R. amblyommii', R.
conorii, R. parkeri, R. prowazekii, R. rickettsii and R. typhi,
and antibodies cross-reactive with E. chaffeensis. We could
not test the patient's serum against the Panola Mountain
Ehrlichia species because this emerging agent has not yet
been cultured. Antibody was detected using isotype-spe-
cific goat antihuman immunoglobulin G (IgG) and
human immunoglobulin M (IgM), labeled with fluores-
cein isothiocyanate (FITC) (KPL, Gaithersburg, Mary-
land). Prior to testing for IgM, sera were depleted of IgG
Table 1: Complete blood count results for blood drawn on 26 
September 2005
Hematocrit 46.7%
Red blood cell count 5.32 × 107/µl
Hemoglobin 15.9 g/dl
Mean corpuscular volume 87.8 fl
Mean corpuscular hemoglobin 29.9 pg
Mean corpuscular hemoglobin concentration 34.1 g/dl
Red blood cell distribution width 12.7%
Platelet count 272,000/µl
White blood cell count 7500/µl
Absolute neutrophils (%) 4868 cells/µl (64.9%)
Absolute lymphocytes (%) 2243 cells/µl (29.9%)
Absolute monocytes (%) 233 cells/µl (3.1%)
Absolute eosinophils (%) 143 cells/µl (1.9%)
Absolute basophils (%) 15 cells/µl (0.2%)Journal of Medical Case Reports 2008, 2:139 http://www.jmedicalcasereports.com/content/2/1/139
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by use of a recombinant Protein G kit (Rapi-Sep-M, Pan-
Bio, Columbia, MD). Acute and convalescent samples
were tested side-by-side, and positive, negative and dilu-
ent controls were assayed with the test samples and gave
expected results. Serology did not support recent infection
with any of the agents tested. With E. chaffeensis antigen,
the patient's serum reacted with a small proportion of the
organisms on the slide, as compared with positive control
sera, and was considered cross-reactive in both acute and
convalescent samples. Titers are expressed as the recipro-
cal of the last dilution exhibiting specific fluorescence and
were as follows: IgM 32 (26 September), and IgG 16 (26
September) and IgG 32 (15 October). Convalescent IgM
data were not available.
Conclusion
We report that an emerging pathogen, the Panola Moun-
tain  Ehrlichia  species, was detected in blood from a
human patient following the bite of a nymphal Amblyo-
mma  that was probably acquired at Panola Mountain
State Park in Georgia in the United States of America. The
Panola Mountain Ehrlichia  species was originally
described from a goat fed upon by A. americanum col-
lected at this park [4], but this is the first report associating
the agent with human illness.
The Panola Mountain Ehrlichia  species is genetically
closely related to E. ruminantium and more distantly
related to E. chaffeensis [4]. The patient exhibited myalgia
for 3 weeks prior to presentation, had ehrlichemia, which
was confirmed by DNA sequencing at presentation, and
rapidly recovered after treatment with doxycycline.
Although PCR and serological testing for other tick-borne
agents was negative, suggesting that ehrlichiosis was the
cause of illness, we cannot conclusively rule out the possi-
bility that the patient's symptoms were caused by an
unknown factor. Serological confirmation of infection
with the Panola Mountain Ehrlichia species could not be
obtained, with only a two-fold rise in IgG titer between
the two serum samples. This might be due to the initiation
of antibiotic therapy prior to optimal immune response
or due to the lack of an appropriate antigen; antibodies
against ehrlichial agents are often, but not always, cross-
reactive with other species of Ehrlichia [3]. In this case,
PCR testing of whole blood was of significantly greater
diagnostic value than serological testing.
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